BEIJING, Aug. 8 /Xinhua-PRNewswire-FirstCall/ -- Yongye Biotechnology International, Inc. (OTC Bulletin Board: YGYB) ("Yongye" or the "Company"), a leading developer, producer and distributor of nutrients for plants and animals in the People's Republic of China, today announced that it has retained CCG Investor Relations to assist in the design and execution of its investor relations program.
Yongye is engaged in the development, distribution and sales of fulvic acid based liquid and powder nutrients for plants and animals. Yongye currently markets and sells its nutrients for plants in ten provinces and its nutrients for animals in four provinces. The Company sold 106,000 units (approximately 1,100 metric tons) of nutrients for plants and 13,800 units (approximately 4 metric tons) of nutrients for animals in 2007. Nutrients for plants contributed 87%, and nutrients for animals contributed 13%, of the Company's $13.1 million total revenue in 2007. In the first quarter of 2008, the Company sold 75,500 units of nutrients for plants (approximately 756 metric tons) and 47,035 units of nutrients for animals (approximately 14 metric tons), which contributed 83% and 17%, respectively, of the Company's $9.5 million total revenue.
"Our proprietary technology for fulvic acid extraction produces some of the purest and most bioactive fulvic acid in China. We combine this fulvic acid base with other ingredients using our proprietary formulae to create some of the most effective nutrients for plants and animals available in China. We plan to increase distribution and sales within our existing markets in the third and fourth quarters of 2008, and help our customers consistently achieve reliable results through use of our high quality products," said Mr. Zishen Wu, Chairman and CEO of Yongye Biotechnology International, Inc. "Along with expanding our operations, we look forward to working with CCG to improve our visibility in the investment community and with the financial media."
"China has a total of 155 million hectares of arable farmland. China's large population means that its arable farmland must feed an average of 10 people per hectare compared to a worldwide average of 4.4 people per hectare. China's farmland is currently being used at close to capacity levels just to meet domestic demand. A combination of limited arable land and a large and growing population has created a significant need to increase output per hectare in China," commented Crocker Coulson, President of CCG Investor Relations. "We look forward to helping Yongye achieve a strong dialogue with US investors."
About Yongye Biotechnology International, Inc.
Yongye Biotechnology International, Inc., headquartered in Beijing, is engaged in the development, distribution and sales of fulvic acid based nutrients for plants and animals. The Company's patent pending processes and proprietary formulas allow it to create products which increase crop yields and improve the health of livestock. Its sole operating subsidiary, Yongye Nongfeng Biotechnology Company, Ltd., is located in Inner Mongolia. The Company sells its products through distributors and directly to farmers located in ten provinces throughout China.
Certain statements set forth in this press release constitute "Forward-
looking statements" within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements include, without limitation,
any statement that may predict, forecast, indicate, or imply future
results, performance or achievements, and may contain the words "estimate,"
"project," "intend," "forecast," "anticipate," "plan," "planning,"
"expect," "believe," "will," "will likely," "should," "could," "would,"
"may" or words or expressions of similar meaning. All such forward-looking
statements involve risks and uncertainties, including, but not limited to:
statements regarding the Company's products; marketing and sales; patents
and regulatory approvals; the effect of competition and proprietary rights
of third parties; the need for and availability of additional financing and
access to capital; the seeking of joint development, licensing or
distribution and collaboration and marketing arrangements with other
companies. There can be no assurance that such forward-looking statements
will prove to be accurate and Yongye undertakes no obligation to update any
forward-looking statements or to announce revisions to any of the
For more information, please contact:
Yongye Biotechnology International, Inc.
Mr. Larry Gilmore-VP of Corporate Strategy
CCG Investor Relations, Inc.
Mr. Crocker Coulson, President
Tel: +1-646-213-1915 (New York)
|SOURCE Yongye Biotechnology International, Inc.|
Copyright©2008 PR Newswire.
All rights reserved